Your new post is loading...
On September 6, 2022, the U.S. Food and Drug Administration cleared the way for marketing of a rapid-acting brain-stimulation approach for major depressive disorder pioneered by Nolan Williams, M.D., of Stanford University, and colleagues. Dr. Williams is a 2018 and 2016 BBRF Young Investigator and winner of the 2019 BBRF Klerman Prize for Exceptional Clinical Research.
